denkapparat Operations GmbH Invests $212,000 in Solventum Co. (NYSE:SOLV)

denkapparat Operations GmbH acquired a new stake in Solventum Co. (NYSE:SOLV) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,208 shares of the company’s stock, valued at approximately $212,000.

A number of other hedge funds also recently added to or reduced their stakes in SOLV. New York Life Investment Management LLC boosted its position in Solventum by 0.7% during the fourth quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock valued at $1,223,000 after purchasing an additional 136 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Solventum by 2.1% in the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after buying an additional 161 shares in the last quarter. MML Investors Services LLC grew its position in shares of Solventum by 3.2% in the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after buying an additional 168 shares during the last quarter. Avantax Advisory Services Inc. raised its stake in shares of Solventum by 2.2% during the 4th quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after acquiring an additional 192 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Solventum by 48.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company’s stock valued at $45,000 after acquiring an additional 223 shares during the last quarter.

Solventum Trading Down 1.0 %

Shares of Solventum stock opened at $74.78 on Friday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock has a market cap of $12.94 billion and a PE ratio of 27.19. The firm has a fifty day moving average price of $75.51 and a 200 day moving average price of $71.83.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Mizuho upped their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Wells Fargo & Company increased their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. The Goldman Sachs Group boosted their price target on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research note on Monday, March 3rd. Piper Sandler increased their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Finally, Morgan Stanley boosted their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.